Etoposide: A pharmacokinetic profile including an assessment of bioavailability
- 30 Downloads
The pharmacokinetics of intravenous etoposide (50–150 mg m−2) have been studied in 17 patients. Bioavailability studies on either the capsule or intravenous (i.v.) formulation were performed in 13 patients, 7 of whom received both oral formulations given in the dose range 50–250 mg m−2. After i.v. administration the mean±SD half-lives weret 1/2α 0.62±1.01 h andt 1/2β 6.04±2.5 h. The bioavailability of etoposide was extremely variable: for the capsule it was 38±14% (range 10–55) and for the i.v. formulation it was 53±25% (range 31–88). The i.v. formulation was not significantly better than the capsule. The results confirm the low and variable bioavailability of oral etoposide.
Key wordsEtoposide Pharmacokinetics Bioavailability
Unable to display preview. Download preview PDF.
- 2.D’Incalci M, Farina P, Sessa Cet al: Pharmacokinetics of VP16-213 given by different administration methods.Cancer Chemother Pharmac 7, 141 (1982).Google Scholar
- 3.Harvey V J, Slevin M L, Joel S Pet al: The pharmacokinetics of oral etoposide (VP16-213).Proc Am Soc Clin Oncol 3, 24 (1984).Google Scholar
- 5.Stewart D J, Nundy D, Maroun J Aet al: Biovailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.Cancer Treatment Rep 69, 269 (1985).Google Scholar